Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Switching among multiple infliximab biosimilars does not cause immunogenicity

Switching among multiple infliximab biosimilars does not cause immunogenicity

Presented By
Dr Jéróme Avouac, Paris Descartes University, France
Conference
EULAR 2019
Immunogenicity does not constitute a barrier to interchangeability between biosimilars infliximab in chronic inflammatory diseases. “There are still consequences of immunogenicity that are not negligible with increased risk of allergic reactions, even though they were quite low in our cohort,” concluded Dr Jéróme Avouac (Paris Descartes University, France) [1]. The use of biosimilars has taken off in the past few years and is expected to increase further. The debate on the use of biosimilars and the switching from reference biologic medicines to biosimilars in rheumatology focuses on the clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy for patients. Dr Avouac et al. aimed to determine whether the successive switches from innovator infliximab to a first then second biosimilar increased the risk of immunogenicity during a 3-year observation period. This was done as a prospective, single-centre, observati...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on